Averion, Trio Clinical Research, Fulcrum Pharma and ClinResearch/ADDPLAN have merged together to form a new biopharmaceutical and medical device development services organisation.
The merger, led by a group of investors including The Halifax Group, SV Life Sciences and the Comvest Group, is part of a strategy to address the constant pressures and challenges currently facing the pharmaceutical, biotech and medical device industries through a different service offering.
Patrick Donnelly, formerly the CEO and one of the founders of PRA International, was named Chairman and CEO of the new group and Matthew Bond, formerly of PRA International as well, will be joining as the chief financial officer.
Donnelly said that with the new financial partnership and the combination of services from each company, they could offer clients access to over 800 professionals that can provide comprehensive and proven development capabilities.